Related Experiment Video
Updated: Jun 5, 2025
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Extracellular vesicles role in radio(nuclide)therapy
1Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Équipe Labellisée Ligue Contre le Cancer, 208 rue des apothicaires, 34298 Montpellier, France.
Targeted radionuclide therapy stimulates the immune system by releasing extracellular vesicles from irradiated cells. This approach shows promise for overcoming resistance to immune checkpoint inhibitors and enhancing antitumor immunity.
Area of Science:
- Oncology
- Immunology
- Radiotherapy
Background:
- Conventional radiation therapy can induce immunogenic cell death.
- Targeted radionuclide therapy (TRT) delivers continuous low-dose radiation to tumors.
- TRT shows potential in overcoming resistance to immune checkpoint inhibitors.
Purpose of the Study:
- To examine preclinical and clinical findings on TRT's immunomodulatory effects.
- To investigate the role of extracellular vesicles in TRT-induced antitumor immunity.
Main Methods:
- Review of preclinical studies.
- Analysis of clinical findings.
- Investigation of extracellular vesicle release from irradiated cells.
Main Results:
- Irradiated cells release extracellular vesicles that activate the immune system.
- TRT stimulates antitumor immunity.
- Extracellular vesicles contribute to immune activation following TRT.
Conclusions:
- Targeted radionuclide therapy activates the immune system.
- Extracellular vesicle release is a key mechanism for TRT-induced antitumor immunity.
- TRT is a promising strategy for enhancing cancer immunotherapy.
